Sort
82,697 grants matching “vaccine development”
Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization
$2,100,000Kenneth D Stuart · Seattle Children'S Hospital · U19 · FY2023 · AI
Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs
$2,099,783Leonidas A Stamatatos · Fred Hutchinson Cancer Center · U19 · FY2023 · AI
Development of therapeutic pan-Alphavirus human monoclonal antibodies
$2,099,526Michael S. Diamond · La Jolla Institute For Immunology · U19 · FY2023 · AI
Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages
$2,099,464Barton F Haynes · Duke University · U19 · FY2022 · AI
DNA Vaccines
$2,099,304George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU)
$2,099,237Amita Gupta · Johns Hopkins University · UM1 · FY2023 · AI
Advanced anthrax vaccine made with ISS DNA formulations
$2,098,735Gary A Van Nest · Dynavax Technologies Corporation · U01 · FY2006 · AI
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
$2,098,592Karen L. Kotloff · University Of Maryland Baltimore · UM1 · FY2022 · AI
Advanced Development of Vaccines for Infectious Diseases
$2,098,124Ly Phan · Versatope Therapeutics, Inc. · N01 · FY2019 · AI
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana
$2,095,803Roger L Shapiro · Harvard University D/B/A Harvard School Of Public Health · U01 · FY2024 · AI
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
$2,095,587Karen L. Kotloff · University Of Maryland Baltimore · UM1 · FY2021 · AI
Integrative analysis and modeling of human immune responses and pathologies
$2,095,068John Tsang · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Rhinovirus Infections and Childhood Asthma
$2,094,533Robert F Lemanske · University Of Wisconsin-Madison · P01 · FY2012 · HL
Flavivirus Infections: Pathogenesis and Prevention
$2,094,472Alan L Rothman · University Of Rhode Island · P01 · FY2011 · AI
MU-JHU HPTU TRIAL SITE - UGANDA
$2,094,277Johns Hopkins University · U01 · FY2001 · AI
Dry Season Ecology of Malaria Vectors
$2,094,113Thomas E Wellems · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Mayo Clinic Ovarian Cancer SPORE
$2,093,975Scott H Kaufmann · Mayo Clinic Rochester · P50 · FY2025 · CA
Chicago Clinical Trials Unit
$2,093,731Babafemi O Taiwo · Northwestern University At Chicago · UM1 · FY2019 · AI
Task V06: Process development and manufacture of cGMP compliant parvovirus B19 vaccine drug product for use in Phase I/II clinical trials
$2,093,700Timothy Fouts · Advanced Bioscience Laboratories, Inc. · N01 · FY2019 · AI
Modeling Early Immunity to Human Influenza Infection
$2,093,547Stuart C. Sealfon · Icahn School Of Medicine At Mount Sinai · U19 · FY2018 · AI
ADVANCING VACCINE ADJUVANT RESEARCH FOR TUBERCULOSIS (AVAR-T)
$2,091,723Warwick Britton · University Of Sydney · N01 · FY2024 · AI
Genetic and Biochemical Approaches to Tyrosine Kinase and Lymphocyte Signaling
$2,091,371Pamela Schwartzberg · National Human Genome Research Institute · ZIA · FY2015 · HG
Research Project 3: Rapid-Response Roadmap for RNA vaccines
$2,091,310Jesse Hong-Sae Erasmus · Albert Einstein College Of Medicine · U19 · FY2024 · AI
Washington University SPORE in Pancreatic Cancer
$2,091,214David G Denardo · Washington University · P50 · FY2024 · CA
Non-Human Primate Core
$2,091,106Mario Roederer · National Institute Of Allergy And Infectious Diseases · ZIC · FY2009 · AI